Tag:

AbbVie

Latest Headlines

Latest Headlines

Big Pharma joins the U.K.'s genomics project with eyes on drug discovery

A group of the world's leading drugmakers have joined the U.K.'s ambitious initiative to sequence the genomes of 100,000 Britons, mining the data with hopes of finding new pathways to treat cancer and rare diseases.

What does Merck's $10B buyback plan say about pharma M&A?

Adding $10 billion to its stock buyback program might mean Merck & Co. wants to keep investors happy as its sales continue to shrink. That would be the typical explanation. But  The Wall Street Journal  sees a different possibility--one the rest of the industry might want to pay attention to.

Opdivo, Praluent and LCZ-696 top a launch crop poised for $27B in sales

What's better than a new drug launch? A launch destined for greatness, of course. For sales and marketing teams, that's about as much job security as you can get. 

Which diseases are driving drug spending hikes? It's not just hep C

Industry watchers well know that U.S. drug spending is rising--a lot. And they also know that it's likely to continue over the next few years if some major changes don't occur. But which medical conditions will be responsible for the swelling tide? Some of those may surprise you.

Google's Calico widens its R&D net with QB3 partnership

Calico, the Google-backed biotech with ambitions to decode the aging process, has aligned itself with California's QB3, a Bay Area brain trust, to further flesh out its R&D mission.

AbbVie's $21B buyout puts Pharmacyclics execs in line for $4B payoff

Pharmacyclics CEO Robert Duggan would add $3.5 billion to his already substantial wealth, if and when AbbVie's $21 billion buyout goes through. But considering Duggan's record, a multibillion-dollar payoff is to be expected. It's the other executives and directors--who together qualify for more than $575 million--who could inspire M&A envy.

AbbVie CEO pads $16M paycheck with $500K in jet travel

For the first couple of years after AbbVie's debut as an independent pharma company, its CEO, Richard Gonzalez, didn't quite follow in Abbott Laboratories CEO Miles White's footsteps compensation-wise, collecting a mere $8 million in 2012 pay. But for 2014, Gonzalez's total compensation amounted to $22 million, according to AbbVie's proxy statement.

Big Pharma's market cap stars of 2014: Lilly, AbbVie, AstraZeneca

Who can resist a numbers match-up? Not us, obviously. Even better when the winners are a bit unexpected. Today, it's market cap, courtesy of EvaluatePharma and its annual state of the industry report.

Imbruvica cocktail stalls CLL in new trial, raising hopes for bigger market

After agreeing to shell out a pretty penny for Imbruvica-maker Pharmacyclics earlier this month, AbbVie chief Richard Gonzalez assured investors that the drug had plenty of market growth ahead--and that much of that growth would come from moving into earlier lines of treatment in its approved indications, including CLL. Now, new Phase III results suggest the med is on the right track in that department.

UPDATED: Just where does AbbVie expect to find $7B in Imbruvica sales?

For some industry watchers, AbbVie's $21 billion pact to buy Imbruvica-maker Pharmacyclics begged a lot of questions. For instance, after the company agreed to pay a price that steep--or "lofty," "staggering," and even "astronomical," to use analysts' words--how much would Imbruvica actually rack up in peak sales? And where would those sales come from?